Meisheng Lu

Title: Meisheng Lu: Innovator in Antibody Research

Introduction

Meisheng Lu is a prominent inventor based in Houston, TX (US). He has made significant contributions to the field of antibody research, holding a total of 4 patents. His work focuses on developing inhibitors that target specific proteins involved in various diseases.

Latest Patents

One of his latest patents is titled "Nucleic acids encoding antibody 137-26 which binds C5 and C5a." This invention relates to inhibitors that bind to C5 and C5a without preventing the activation of C5 or inhibiting the activity of C5b. The monoclonal antibody designated MAb137-26 is a key example, as it binds to a shared epitope of human C5 and C5a. These inhibitors are designed to inhibit the activity of C5a, which is crucial in treating diseases characterized by excessive or uncontrolled production of C5a. Additionally, the inhibitor molecules are valuable for diagnostic detection of the presence or amount of C5 or C5a.

Another significant patent is "Anti-C5/C5a antibodies and methods of use," which shares similar objectives and applications as the previous patent. Both inventions highlight the potential of these inhibitors in therapeutic and diagnostic settings.

Career Highlights

Meisheng Lu is currently associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His work at Genentech has allowed him to further his research and contribute to advancements in medical science.

Collaborations

Throughout his career, Meisheng Lu has collaborated with notable colleagues, including Michael Fung and William N C Sun. These collaborations have enriched his research and expanded the impact of his inventions.

Conclusion

Meisheng Lu's contributions to antibody research and his innovative patents demonstrate his commitment to advancing medical science. His work has the potential to significantly impact the treatment and diagnosis of diseases related to C5 and C5a.